Nasal spray may reduce breathing risks during ERCP
NCT ID NCT07204106
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a dexmedetomidine nasal spray to the usual sedative propofol could reduce breathing problems during ERCP, a procedure to treat bile duct issues. 180 adults were split into three groups: one got the nasal spray plus propofol, another got dexmedetomidine through an IV plus propofol, and the third got propofol alone. The main goal was to see if the nasal spray lowered the chance of low blood oxygen levels during the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dexmedetomidine nasal spray
- What this could lead to
- If it works, this could offer a safer sedation method for ERCP with fewer breathing issues.
- What could go wrong
- This is a small, completed study. Results may not apply to all patients, and side effects like low blood pressure or slow heart rate are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEXMEDETOMIDINE INDUCED SEDATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai East Hospital,Affiliated to Tongji University
Shanghai, Shanghai Municipality, 200120, China